Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Thrasos Therapeutics Resource Report Resource Website |
Thrasos Therapeutics (RRID:SCR_004052) | Thrasos | commercial organization | Private, clinical stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. They are committed to developing novel approaches to protect, treat and restore kidney function for this patient group. Company has designed specific class of peptide compounds that have shown excellent results in controlling experimental kidney diseases, notably, models of diabetic nephropathy (kidney damage associated with diabetes), and acute kidney injury. These proprietary peptides may therefore be able to prevent and treat acute kidney injury, as well as slow and possibly reverse the progression of diabetic nephropathy. They act to control apoptosis (programmed cell death), inflammation and fibrosis (formation of scar tissue). | Controlling experimental kidney diseases, biotherapeutics, clinical, peptide, treat acute kidney injury, reverse progression diabetic nephropathy | is related to: Kidney Health Initiative | Kidney disease, Acute kidney injury, Diabetic nephropathy, Chronic kidney disease | nlx_158489 | http://www.thrasos.com/ | SCR_004052 | Thrasos Innovation Inc. | 2026-02-14 02:00:40 | 0 | ||||||
|
MPS Hamburg Resource Report Resource Website 1+ mentions |
MPS Hamburg (RRID:SCR_004087) | MPS | commercial organization | Full service Clinical Research Organization (CRO) in Hamburg, Germany, mainly focusing on phase-I and phase-IIa clinical trials. MPS owns 72 bed research clinic with 6 physicians and 15 nurses as permanent staff. MPS is experienced in performing all kind of early stage clinical trials, including first-in-man-trials, medical-devices-trials, nutraceutical and consumer-goods-trials. MPS holds active database of more than 17,000 healthy volunteers, plus hundreds of patients in special populations. | clinical trial, clinical, medical device, patient registry, healthy, nutraceutical, consumer-goods, pharmaceutical | is related to: European Gram Negative AntiBacterial Engine | nlx_158544 | SCR_004087 | MPS Hamburg GmbH | 2026-02-14 02:00:36 | 1 | ||||||||
|
Big Ten Cancer Research Consortium Resource Report Resource Website |
Big Ten Cancer Research Consortium (RRID:SCR_004025) | BTCRC | data or information resource, organization portal, portal, consortium | A consortium that aims to transform cancer research through collaborative oncology trials that leverage the scientific and clinical expertise of the Big Ten universities. The goal is to align the conduct of cancer research through collaborative, hypothesis-driven, highly translational oncology trials that leverage the scientific and clinical expertise. The clinical trials that will be developed will be linked to molecular diagnostics, enabling researchers to understand what drives the cancers to grow and what might be done to stop them from growing. The consortium also leverages geographical locations and existing relationships among the cancer centers. One of the consortium's goals is to harmonize contracts and scientific review processes to expedite clinical trials. The consortium will only focus on phase 0 to II trials because larger trials - even a randomized phase II trial - are difficult to conduct at a single cancer center. | oncology, drug development, basic research, clinical trial, clinical, genitourinary, gastrointestinal, thoracic, breast, nanotechnology, virus, triple-negative cell |
is affiliated with: Penn State Milton S. Hershey Medical Center; Pennsylvania; USA is affiliated with: University of Wisconsin-Madison; Wisconsin; USA is affiliated with: Rutgers University; New Jersey; USA is affiliated with: Northwestern University; Illinois; USA is affiliated with: University of Nebraska; Nebraska; USA is affiliated with: University of Minnesota Twin Cities; Minnesota; USA is affiliated with: Michigan State University; Michigan; USA is affiliated with: University of Michigan; Ann Arbor; USA is affiliated with: University of Iowa; Iowa; USA is affiliated with: Indiana University; Indiana; USA is affiliated with: University of Illinois College of Medicine; Illinois; USA has parent organization: Hoosier Cancer Research Network |
Cancer | Public | nlx_158452 | SCR_004025 | Big Ten CRC | 2026-02-14 02:00:39 | 0 | ||||||
|
EU-ADR Resource Report Resource Website 1+ mentions |
EU-ADR (RRID:SCR_004028) | EU-ADR | data or information resource, organization portal, portal, consortium | Consortium that created the capability to detect Adverse Drug Response (ADR) signals by creating the infrastructure for large-scale monitoring of drug safety using electronic health records (EHR). The platform leverages EHR''''s comprising demographics, drug use and clinical data of over 30 million patients from several European countries. Special attention was given to patient groups that are not routinely involved in clinical trials, for ethical or practical reasons (e.g. pregnant women, elderly people, people using many drugs simultaneously, and children). This project also studies and compares a number of different techniques that all aim to detect unexpected or disproportional rates of events. The algorithms that they studied originate not only from the field of (pharmaco)epidemiology, but also from fields such as bio-terrorism, machine learning, and classical signal detection. EU-ADR specific objectives are: To detect events, To relate these events to drugs, To develop hypothesis that explain adverse events, To detect adverse events earlier, and To avoid false positives. The web-based platform is available at https://bioinformatics.ua.pt/euadr/ EU-ADR has contributed to the ability to conduct better drug safety studies based on the re-use of healthcare data. By facilitating the early detection of adverse drug reactions, but also providing key information on populations at risk, potential drug interactions, potential underlying mechanisms and intervening pathways in adverse events, etc., the project will allow for improved and more complete information to be available for drug and healthcare delivery, leading to increased patient safety and its associated cost savings. The EU-ADR system can be considered as a complementary tool to already existing pharamcovigilance systems. Should the system be widespread in the long term, it has the potential to contribute to the development of future electronic health record systems, insofar as the expected benefits of these IT tools are only fully attainable when EHRs develop themselves in consistency, richness and formats that allow them to be subject of such tools. In anticipation, EU-ADR has been designed to be modular and scalable, so that different EHR databases (other than those participating in the Consortium) can be progressively enlisted in the future, adopt the software for data extraction and therefore become susceptible of exploitation by the system, for maximum global effect. | adverse drug reaction, clinical, biomedical, drug safety, electronic health record, demographic, drug use, clinical data, late adult human, child, young human, pregnant, drug, adverse event, signal detection, drug development, data sharing, text mining, epidemiology, database, data set, data repository, text extraction software |
is listed by: Consortia-pedia is related to: Mar Institute of Medical Research Foundation is related to: University of Aveiro; Aveiro; Portugal has parent organization: Mar Institute of Medical Research Foundation has parent organization: University of Aveiro; Aveiro; Portugal |
European Union FP7 | nlx_158456 | SCR_004028 | Exploring and Understanding Adverse Drug Reactions by Integrative Mining of Clinical Records and Biomedical Knowledge | 2026-02-14 02:00:35 | 9 | |||||||
|
Hoosier Cancer Research Network Resource Report Resource Website |
Hoosier Cancer Research Network (RRID:SCR_004026) | HCRN | nonprofit organization | An independent nonprofit cancer research organization that provides full-service clinical trial management and support, from conception and study design through project completion and publication. Established to explore and develop leading edge cancer treatments across the United States and internationally, their clinical trials, developed in collaboration with academic and community oncologists, are conducted within a member network of more than 130 clinical research sites. Their vision and mission is to form unparalleled relationships between academic, community, pharmaceutical, and biotech partners with the goal of advancing cancer research, education, and patient advocacy. There are no costs to become a member. | oncology, clinical trial, clinical | is parent organization of: Big Ten Cancer Research Consortium | Cancer | nlx_158453, Wikidata: Q30287333, grid.428706.f | https://ror.org/02mtpb511 | SCR_004026 | Hoosier Oncology Group | 2026-02-14 02:00:55 | 0 | ||||||
|
EGAPP Resource Report Resource Website 1+ mentions |
EGAPP (RRID:SCR_004189) | EGAPP | data or information resource, portal, topical portal | Initiative to develop a systematic, evidence-based process for evaluating genetic tests and other applications of genomic technology that are rapidly moving from research to use in clinical practice. A key objective of this process is to provide objective, timely, and credible information that is clearly linked to the scientific evidence on specific applications of genetic and genomic tests. The primary focus of EGAPP activities is an independent, nonfederal expert panel, the EGAPP Working Group. Other components of the EGAPP initiative include a federal interagency, the CDC staff and consultants, and an EGAPP initiative evaluation team. | genetic test, genomics, clinical, genomic technology, evaluation, public health |
is listed by: OMICtools has parent organization: Centers for Disease Control and Prevention |
OMICS_01538 | SCR_004189 | Evaluation of Genomic Applications in Practice and Prevention (EGAPP), Evaluation of Genomic Applications in Practice and Prevention | 2026-02-14 02:00:41 | 1 | ||||||||
|
Wellcome Images Resource Report Resource Website |
Wellcome Images (RRID:SCR_004181) | Wellcome Images | data repository, storage service resource, image collection, data or information resource, service resource, image repository, database | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 9, 2023.Digital collection of images, with themes ranging from medical and social history to contemporary healthcare and biomedical science. The collection contains historical images from the Wellcome Library collections, Tibetan Buddhist paintings, ancient Sanskrit manuscripts written on palm leaves, beautifully illuminated Persian books and much more. The Biomedical Collection holds over 40 000 high-quality images from the clinical and biomedical sciences. Selected from the UK''s leading teaching hospitals and research institutions, it covers disease, surgery, general healthcare, sciences from genetics to neuroscience including the full range of imaging techniques. They are always looking for new high quality biomedical images from scientific researchers, clinical photographers and artists in any field of science or medicine. As a contributor you retain your original material and copyright, and receive commission and full credit each time your images are used. The annual Wellcome Images awards (previously known as Biomedical Images Awards) reward contributors for their outstanding work and winners are chosen by a panel of experts. The resulting public exhibitions are always extremely popular and receive widespread acclaim. All images on the Wellcome Images site are available free for use in: * private study and non-commercial research * examination papers * criticism and review, this applies only where there are no multiple copies made * theses submitted by a student at a higher or further education institution for the purposes of securing a degree * personal use by private individuals | biomedical, clinical, disease, surgery, healthcare, genetics, neuroscience, imaging, science, medicine, history, painting, manuscript | Wellcome Trust | THIS RESOURCE IS NO LONGER IN SERVICE | r3d100010779, nlx_143611 | https://doi.org/10.17616/R3HS58 | SCR_004181 | 2026-02-14 02:00:56 | 0 | |||||||
|
Strong Star Resource Report Resource Website |
Strong Star (RRID:SCR_003132) | STRONG STAR | portal, clinical trial, data or information resource, research forum portal, disease-related portal, topical portal | A multidisciplinary and multi-institutional research consortium to develop and evaluate the most effective early interventions possible for the detection, prevention, and treatment of combatrelated posttraumatic stress disorder (PTSD) in activeduty military personnel and recently discharged veterans. Complementary investigations are focused on the root causes of PTSD, including biological factors that influence PTSD susceptibility and recovery; the influence of comorbid physical and psychological ailments; and the interaction of cognitive-behavioral therapies and pharmacologic treatments. The full cohort of STRONG STAR trials include: Treatment Studies, Biological Studies, Epidemiological Studies, and Preclinical Studies. STRONG STAR is currently conducting three clinical treatment trials at Carl R. Darnall Army Medical Center (CRDAMC). The studies are examining the effectiveness of Cognitive Processing Therapy (CPT), Prolonged Exposure Therapy (PE) and Cognitive Behavioral Therapy for Insomnia (CBTi) with active duty service members. Treatments are offered in individual, group, and online formats, and last from two to eight weeks. Study participants must be active duty service members who will remain in the Ft Hood area for at least 34 months to complete initial assessments and treatment programs. Referrals to the treatment studies can be made through a behavioral health provider or through selfreferral., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025. | treatment, military, cognitive processing therapy, prolonged exposure therapy, cognitive behavioral therapy, detection, prevention, diagnosis, active duty, veteran, clinical, pharmacologic treatment, preclinical, combat-related post-traumatic stress disorder | has parent organization: University of Texas Health Science Center at San Antonio; Texas; USA | Post-Traumatic Stress Disorder, Insomnia | United States Department of Defense | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_156784 | SCR_003132 | South Texas Research Organizational Network Guiding Studies on Trauma and Resilience | 2026-02-14 02:00:40 | 0 | |||||
|
Measurement Method Ontology Resource Report Resource Website |
Measurement Method Ontology (RRID:SCR_003373) | MMO | data or information resource, ontology, controlled vocabulary | An ontology designed to represent the variety of methods used to make qualitative and quantitative clinical and phenotype measurements both in the clinic and with model organisms. | obo, phenotype, clinical |
is listed by: SourceForge is listed by: BioPortal is listed by: OBO |
PMID:22654893 | Free, Available for download, Freely available | nlx_157468 | http://sourceforge.net/projects/phenoonto/ ftp://rgd.mcw.edu/pub/ontology/measurement_method/measurement_method.obo |
SCR_003373 | 2026-02-14 02:00:47 | 0 | ||||||
|
Malaria Ontology Resource Report Resource Website |
Malaria Ontology (RRID:SCR_003369) | IDOMAL | data or information resource, ontology, controlled vocabulary | An application ontology to cover all aspects of malaria (clinical, epidemiological, biological, etc) as well as the intervention attempts to control it, extending the infectious disease ontology (IDO). | obo, health, pathological, clinical, epidemiological, biological, intervention |
is listed by: BioPortal is listed by: OBO has parent organization: AnoBase: An Anopheles database |
Malaria | Free, Available for download, Freely available | nlx_157464 | http://purl.obolibrary.org/obo/idomal.obo http://anobase.vectorbase.org/idomal/IDOMAL.obo |
SCR_003369 | 2026-02-14 02:00:32 | 0 | ||||||
|
eDoctoring Resource Report Resource Website 1+ mentions |
eDoctoring (RRID:SCR_003336) | eDoctoring | training service resource, training resource, data or information resource, service resource, continuing medical education, narrative resource, training material | Online educational tool that brings challenging clinical practice to your computer, providing medical education that is engaging, challenging and interactive. While there is no substitute for real-life direct contact with patients or colleagues, research has shown that interactive online education can be a highly effective and enjoyable method of learning many components of clinical medicine, including ethics, clinical management, epidemiology and communication skills. eDoctoring offers 25 simulated clinical cases, 15 interactive tutorials and a virtual library containing numerous articles, fast facts and video clips. Their learning material is arranged in the following content areas: * Ethical, Legal and Social Implications of Genetic Testing * Palliative and End-of-Life Care * Prostate Cancer Screening and Shared Decision-Making | clinical, medical education, medical, clinical medicine, ethics, clinical management, epidemiology, communication, legal, social, implication, genetic testing, palliative care, end-of-life care, prostate cancer screening, decision-making, prostate cancer, medicine, tutorial, article, video, fact, training material |
has parent organization: Newcastle University; Newcastle upon Tyne; United Kingdom has parent organization: University of California; California; USA |
NCI ; NIH ; CDC ; NHGRI ; Health Resources and Services Administration ; Paul G. Allen Family Foundation ; Robert Wood Johnson Foundation |
THIS RESOURCE IS NO LONGER IN SERVICE | nif-0000-31964 | http://edoctoring.ncl.ac.uk/System_Check/psa_detect_html;clickonRouletteWheels | SCR_003336 | 2026-02-14 02:00:32 | 1 | ||||||
|
Clinical Measurement Ontology Resource Report Resource Website |
Clinical Measurement Ontology (RRID:SCR_003291) | CMO | data or information resource, ontology, controlled vocabulary | An ontology designed to be used to standardize morphological and physiological measurement records generated from clinical and model organism research and health programs. | obo, phenotype, clinical, measurement, morphology, physiology |
is listed by: SourceForge is listed by: BioPortal is listed by: OBO has parent organization: Medical College of Wisconsin; Wisconsin; USA |
PMID:22654893 | Free, Freely available | nlx_157364 | http://sourceforge.net/projects/phenoonto/ ftp://rgd.mcw.edu/pub/ontology/clinical_measurement/clinical_measurement.obo |
SCR_003291 | 2026-02-14 02:00:45 | 0 | ||||||
|
caTRIP Resource Report Resource Website 1+ mentions |
caTRIP (RRID:SCR_003409) | caTRIP | data analysis software, software resource, data processing software, software application | THIS RESOURCE IS NO LONGER IN SERVICE documented June 4, 2013. Allows users to query across a number of caBIG data services, join on common data elements (CDEs), and view results in a user-friendly interface. With an initial focus on enabling outcomes analysis, caTRIP allows clinicians to query across data from existing patients with similar characteristics to find treatments that were administered with success. In doing so, caTRIP can help inform treatment and improve patient care, as well as enable the searching of available tumor tissue, enable locating patients for clinical trials, and enable investigating the association between multiple predictors and their corresponding outcomes such as survival caTRIP relies on the vast array of open source caBIG applications, including: * Tumor Registry, a clinical system that is used to collect endpoint data * cancer Text Information Extraction System (caTIES), a locator of tissue resources that works via the extraction of clinical information from free text surgical pathology reports. while using controlled terminologies to populate caBIG-compliant data structures * caTissue CORE, a tissue bank repository tool for biospecimen inventory, tracking, and basic annotation * Cancer Annotation Engine (CAE), a system for storing and searching pathology annotations * caIntegrator, a tool for storing, querying, and analyzing translational data, including SNP data Requires Java installation and network connectivity. | element, clinical, patient, structure, tissue, trial, tumor, common data element, clinician, data technician, java, outcomes research, ctsa | has parent organization: Cancer Biomedical Informatics Grid | NCI | THIS RESOURCE IS NO LONGER IN SERVICE | nif-0000-33400 | SCR_003409 | 2026-02-14 02:00:48 | 2 | |||||||
|
miniTUBA Resource Report Resource Website |
miniTUBA (RRID:SCR_003447) | miniTUBA | production service resource, service resource, analysis service resource, storage service resource | miniTUBA is a web-based modeling system that allows clinical and biomedical researchers to perform complex medical/clinical inference and prediction using dynamic Bayesian network analysis with temporal datasets. The software allows users to choose different analysis parameters (e.g. Markov lags and prior topology), and continuously update their data and refine their results. miniTUBA can make temporal predictions to suggest interventions based on an automated learning process pipeline using all data provided. Preliminary tests using synthetic data and laboratory research data indicate that miniTUBA accurately identifies regulatory network structures from temporal data. miniTUBA represents in a network view possible influences that occur between time varying variables in your dataset. For these networks of influence, miniTUBA predicts time courses of disease progression or response to therapies. minTUBA offers a probabilistic framework that is suitable for medical inference in datasets that are noisy. It conducts simulations and learning processes for predictive outcomes. The DBN analysis conducted by miniTUBA describes from variables that you specify how multiple measures at different time points in various variables influence each other. The DBN analysis then finds the probability of the model that best fits the data. A DBN analysis runs every combination of all the data; it examines a large space of possible relationships between variables, including linear, non-linear, and multi-state relationships; and it creates chains of causation, suggesting a sequence of events required to produce a particular outcome. Such chains of causation networks - are difficult to extract using other machine learning techniques. DBN then scores the resulting networks and ranks them in terms of how much structured information they contain compared to all possible models of the data. Models that fit well have higher scores. Output of a miniTUBA analysis provides the ten top-scoring networks of interacting influences that may be predictive of both disease progression and the impact of clinical interventions and probability tables for interpreting results. The DBN analysis that miniTUBA provides is especially good for biomedical experiments or clinical studies in which you collect data different time intervals. Applications of miniTUBA to biomedical problems include analyses of biomarkers and clinical datasets and other cases described on the miniTUBA website. To run a DBN with miniTUBA, you can set a number of parameters and constrain results by modifying structural priors (i.e. forcing or forbidding certain connections so that direction of influence reflects actual biological relationships). You can specify how to group variables into bins for analysis (called discretizing) and set the DBN execution time. You can also set and re-set the time lag to use in the analysis between the start of an event and the observation of its effect, and you can select to analyze only particular subsets of variables. | analysis, analyze, bayesian, causation, clinical, linear, medical, structure, temporal, network analysis, network, molecule, information refining, gene expression regulation, bioinformatics, statistical package, interaction network, prediction, pathway, inference, biomedical, intervention |
is listed by: Biositemaps has parent organization: National Center for Integrative Biomedical Informatics has parent organization: University of Michigan; Ann Arbor; USA |
Society of University Surgeons Foundation ; NIDA U54DA021519; NIAID 1R21AI057875-01; NIGMS K08 GM074678-01A1 |
PMID:17644819 | Free, Freely available | nif-0000-33272 | SCR_003447 | miniTUBA - Medical Inference by Network Integration of Temporal Data using Bayesian Analysis tool, Medical Inference by Network Integration of Temporal Data using Bayesian Analysis tool, Medical Inference by Network Integration of Temporal Data using Bayesian Analysis tool (miniTUBA), The Medical Inference by Network Integration of Temporal Data using Bayesian Analysis tool | 2026-02-14 02:00:49 | 0 | |||||
|
California Integrated Data Exchange Resource Report Resource Website |
California Integrated Data Exchange (RRID:SCR_003747) | Cal INDEX | data or information resource, organization portal, portal, consortium | A three-year consortium that brings together insurers and health care providers to share information from approximately 9 million patients, with a goal that insights from the data will bring down healthcare costs and improve outcomes. It aims to be one of the largest health information exchanges in the country, with the goal of better connecting the vast, often disparate healthcare landscape across California. The database that will house patient data will be overseen by Orion Health, an independent eHealth software company. The information will only be used for clinical purposes. Academic research institutions can apply to use the Cal INDEX de-identified data for research to benefit the public good, such as population health initiatives. Cal INDEX has five main goals: * Improve the quality of care by providing clinicians with a unified statewide source of integrated patient information * Provide patients with a seamless transition between health plans or across various healthcare professionals and hospitals * Improve efficiency and reduce the cost of healthcare * Encourage healthcare technology innovation * Improve public health by providing de-identified data for medical research. Cal INDEX plans to launch at the end of 2014 with approximately 9 million health information records from combined members of Dignity Health and Blue Shield of California and Anthem Blue Cross. Cal INDEX is open to any health data contributor. Cal INDEX will establish a bi-directional data interface with providers to exchange data with EMRs and other hospital and office-based systems. | healthcare, data sharing, tool development, consortium, health information exchange, health information, health, california, clinical, electronic patient record, database, de-identified | is listed by: Consortia-pedia | Blue Shield of California ; Anthem Blue Cross |
nlx_157980 | SCR_003747 | 2026-02-14 02:00:30 | 0 | ||||||||
|
Advanced Immunization Technologies Resource Report Resource Website 1+ mentions |
Advanced Immunization Technologies (RRID:SCR_003741) | ADITEC | data or information resource, organization portal, portal, consortium | A consortium that aims to accelerate the development of immunization technologies for the next generation of human vaccines. The goals are to characterize the mode of action and conduct comparative effectiveness studies of: adjuvants, vectors, formulations, delivery devices, routes of immunization, homologous and heterologous primeboost schedules, on vaccine efficacy. As part of these clinical trials, the consortium will also investigate the impact of host factors such as age, gender, genetics and pathologies. The consortium hopes to use insights gained from their projects to advance the development of next-generation vaccines, using tools such as standardized animal models to select promising immunization technologies. The intended outcome of this partnership is to improve the vaccine development process by advancing: basic research, new technology development, and clinical trial methods. Scientific objectives: # Development of adjuvants, vectors, formulations, and delivery devices # Selection of candidates, routes of immunization, and prime-boost combinations in animal models # Assessment of the impact of host factors in response to vaccination # Development of concepts and tools from human immunization # Development of concepts and tools to address regulatory and ethical issues posed by novel immunization technologies # Creation of an internationally recognized training program for translational immunology and vaccinology. Data is shared across the research partners within and between the different workstreams. Additionally, the consortium has plans to create a clinical database that combines phenotypic and clinical information to study the immune response to influenza vaccination at a population level, in an effort to advance studies into the effects of genetic background, gender, and disease on vaccine response. | drug, consortium, drug development, biomarker, vaccine, immunization, vaccine technology, adjuvant, vector, route, device, prime-boost, host factor, system biology, technology, animal model, human immunology, immunology, phenotype, clinical, clinical trial, public health | is listed by: Consortia-pedia | European Union FP7 280873 | nlx_157968 | SCR_003741 | Advanced Immunization Technologies (ADITEC) | 2026-02-14 02:00:52 | 8 | |||||||
|
ABIRISK Resource Report Resource Website 10+ mentions |
ABIRISK (RRID:SCR_003740) | ABIRISK | data or information resource, organization portal, portal, consortium | A consortium that seeks to provide an integrated approach to anti-drug immunization by evaluating immunogenicity in hemophilia A, multiple sclerosis, and inflammatory diseases, and exploring new tools for protein drug immunogenicity. The data collected will be pooled in a single immunogenicity databank and will be standardized and used to develop models of anti-drug antibodies. By examining the correlation between patient and clinical factors and the incidence of immunogenicity, it hopes to reduce the regulatory and resource burdens of immunogenicity testing. The objectives of the consortium are: # Access to large cohorts of patients treated with marketed biopharmaceutical products # Complementary expertise for anti-drug antibodies (ADA) assays; standardization and characterization of ADA # Novel integrated approaches to characterize anti-drug lymphocyte responses # Development and validation of innovative prediction tools # Collection and integration of immunogenicity-related data and clinical relevance of ADA ABIRISK is grouped into five working projects, which communicate with one another and provide each other with results and data for analysis. The five working projects are: ADA assay development and validation and cohort management; cellular characterization and mechanisms of the AD immune response; evaluation and development of technologies for predicting immunogenicity; establishment of database, data analyses and integration; and project management and communication. | drug, consortium, drug development, biomarker, pharmacogenomics, biopharmaceutical product, immune response, immunogenicity, data sharing, immune system, biopharmaceutical, clinical |
uses: eTRIKS is listed by: Consortia-pedia |
Innovative Medicines Initiative 115303 | nlx_157967 | SCR_003740 | Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk, ABIRISK Project | 2026-02-14 02:00:35 | 16 | |||||||
|
OncoTrack Resource Report Resource Website 1+ mentions |
OncoTrack (RRID:SCR_003767) | OncoTrack | data or information resource, organization portal, portal, consortium | An international consortium to develop and assess novel approaches to identify and characterize biological markers for colon cancer that will deepen the understanding of the variable make-up of tumors and how this affects the way patients respond to treatment. They will use cutting edge laboratory-based genome sequencing techniques coupled to novel computer modelling approaches to study both the biological heterogeneity of colon cancers (i.e. patient to patient variability) as well as tumor variation within the patient for example, by comparing primary tumors with metastases. This five year project brings together top scientists from European academic institutions offering a wide range of expertise, and partners them with pharmaceutical companies. The project is based on the premise that this genetic and epigenetic information, combined with a description of the molecular pathology of the tumor, will allow OncoTrack to generate a more accurate in-silico model of the cancer cell. This will facilitate the identification of predictive markers that can be used to guide the optimal therapy strategy at the level of the individual patient - and will also provide on-going prognostic guidance for the clinician. This project will not only advance understanding of the fundamental biology of colon cancers but will provide the means and approach for the identification of previously undetected biomarkers not only in the cancer under study, but potentially also in other solid cancers and, in doing so, open the door for personalized management of the oncology patient. | oncology, biomarker, diagnosis, basic science, genome sequencing, computer modelling, genetic, epigenetic, pathology, model, cancer cell, colon, cancer, treatment, genomics, clinical, systems biology, in-silico model, patient variability, tumor variability |
uses: GenomeWeb uses: eTRIKS is listed by: Consortia-pedia is related to: Roche is related to: Janssen Research and Development is related to: Merck is related to: Pfizer Animal Genetics is related to: Charite - Universitatsmedizin Berlin; Berlin; Germany is related to: Max Planck Institute for Molecular Genetics; Berlin; Germany is related to: Medical University of Graz; Graz; Austria is related to: Paris-Sud University; Paris; France is related to: Dresden University of Technology; Saxony; Germany is related to: University College London; London; United Kingdom is related to: Uppsala University; Uppsala; Sweden is related to: Stockholm University; Stockholm; Sweden is related to: Vall d'Hebron Institute of Oncology; Barcelona; Spain is related to: Alacris Theranostics is related to: Experimental Pharmacology and Oncology Berlin-Buch is related to: GABO:mi is related to: International Prevention Research Institute has parent organization: Max Planck Institute for Molecular Genetics; Berlin; Germany |
Innovative Medicines Initiative ; EFPIA |
nlx_158037 | SCR_003767 | OncoTrack - Methods for systematic next generation oncology biomarker development, Onco Track | 2026-02-14 02:00:36 | 9 | |||||||
|
Polycystic Kidney Disease Outcomes Consortium Resource Report Resource Website |
Polycystic Kidney Disease Outcomes Consortium (RRID:SCR_003674) | PKDOC | data or information resource, organization portal, portal, consortium | Consortium to develop evidence supporting the use of imaging Total Kidney Volume (TKV) as a prognostic biomarker that predicts the progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD) to select patients likely to respond to therapy into clinical trials. It aims to replace the currently used measurement of glomerular filtration rate (GFR). Scientists will use the data collected to develop a disease progression model that will evaluate the relationship between TKV and the known complications of ADPKD, including rate of loss of kidney function, hypertension, gross hematuria, kidney stones, urinary tract infections, development of end-stage renal disease, and mortality. These analyses will be used to support the regulatory qualification of TKV as an accepted measure for assessing the progression of ADPKD in clinical trials in which new therapies are tested. PKDOC has the following goals: # Develop standard clinical data elements and definitions that are specific to ADPKD # Create a database of aggregated data from existing multiple, longitudinal, and well-characterized research registries maintained over decades by the leading institutions in ADPKD clinical investigation # Advance and harmonize the missions of regulatory agencies by creating tools that help with the evaluation of new pharmaceutical compounds # Develop a quantitative disease progression model to examine the linkage between TKV and disease outcomes | consortium, drug, imaging, total kidney volume, biomarker, rate, disease progression, imaging biomarker, drug development, kidney volume, kidney, clinical, common data element, therapeutic, clinical trial, standard specification, database |
is listed by: Consortia-pedia has parent organization: Critical Path Institute; Arizona; USA |
PKD Foundation ; Philanthropic donations ; U.S. Food and Drug Administration |
nlx_157909 | SCR_003674 | PKD Outcomes Consortium, PKD Consortium, Polycystic Kidney Disease (PKD) Outcomes Consortium | 2026-02-14 02:00:52 | 0 | |||||||
|
TransCelerate BioPharma Resource Report Resource Website 1+ mentions |
TransCelerate BioPharma (RRID:SCR_003728) | TransCelerate | nonprofit organization | Non-profit research organization aiming to accelerate drug development by increasing the quality and efficiency of clinical studies through the development of shared tools, methods, and platforms. Consortium partnerships are limited to pharmaceutical and biotechnology companies with research & development operations, although there are collaborations with external organizations such the Clinical Data Interchange Standards Consortium (CDISC). Its current focus is to collaborate on: * Standardizing risk-based monitoring * Development of methods to qualify and train clinical trial sites * Development of a common investigator web portal * Development of clinical data standards on efficacy, and methods for comparator drug trials It currently has 5 projects: # Standardized Approach for High-Quality, Risk-Based Monitoring program aims to develop an industry-wide standard and approach for risk-based monitoring of clinical trials in order to enhance patient safety and ensure the quality of clinical trial data. # Shared Site Qualification and Training program aims to standardize GCP training and site qualification credentials in order to realize efficiencies and accelerate study start-up timelines. # Common Investigator Site Portal is a platform designed to streamline investigator and site access through harmonized delivery of content and services. # Data Standards project is a partnership with CDISC to develop industry-wide data standards in priority therapeutic areas to support the exchange and submission of clinical research and meta-data, improving patient safety and outcomes. # Comparator Drugs project aims to establish reliable, rapid sourcing of quality products for use in clinical trials through a comparator supply model enabling accelerated trial timelines and enhanced patient safety. | drug, clinical trial, multipharma, data sharing, drug development, consortium, medicine, clinical, standard specification | is listed by: Consortia-pedia | Member companies financial contributions ; Member companies in-kind contributions ; GlaxoSmithKline |
nlx_157913 | SCR_003728 | TransCelerate BioPharma Inc. | 2026-02-14 02:00:30 | 4 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the NIF Resources search. From here you can search through a compilation of resources used by NIF and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that NIF has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on NIF then you can log in from here to get additional features in NIF such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into NIF you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
Welcome to the Neuroscience Information Framework Project, designed to serve the biomedical research community. NIF maintains the largest searchable collection of neuroscience data, the largest catalog of biomedical resources, and the largest ontology for neuroscience on the web. We welcome all feedback and suggestions and are actively looking for resource providers to make their resources accessible through NIF. Learn about the tools available to help you share your data and discover a dynamic inventory of Web-based neuroscience resources.
